MERS-CoV inhibitor peptides
AssigneeKing Faisal University
InventorsMahmoud Kandeel Elsayed, Abdulla Yousef Al-Taher, Hyung-Joo Kwon, Mohammed Al-Nazawi
Life of this patent
Estimating the term…
Loading patent…
AssigneeKing Faisal University
InventorsMahmoud Kandeel Elsayed, Abdulla Yousef Al-Taher, Hyung-Joo Kwon, Mohammed Al-Nazawi
Estimating the term…
The MERS-CoV inhibitor peptides include a set of peptides designed by modification or mutation of a wild type MERS-CoV fusion protein. The MERS-CoV inhibitor peptides are capable of inhibition of MERS-CoV membrane fusion, and thereby may prevent or slow the spread of MERS-CoV infections. Thus, the MERS-CoV inhibitor peptides may be used in pharmaceuticals to prevent and/or treat MERS-CoV infection. The pharmaceuticals may be formulated to comprise at least one of the MERS-CoV inhibitor peptides and a carrier, or they may include one or more expression systems capable of promoting cellular expression of one or more MERS-CoV inhibitor peptides. The MERS-CoV inhibitor peptides may also be used as reagents for MERS-CoV inhibition assays as a standard or reference inhibitors.
A MERS CoV inhibitor comprising a peptide having the amino acid sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.